Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug discovery and development

Novel anti-platelet therapy shows promise in first human trials

New anti-platelet drug set for phase II study after success in patients with coronary heart disease.

New anti-platelet drug set for phase II study after success in patients with coronary heart disease. Pictured, a blood clot in coronary artery.

Source: Professor P.M. Motta, G. Macchiarelli, S.A Nottola / Science Photo Library

An infusion of PZ-128 resulted in a dose-dependent and rapid inhibition of platelet aggregation in patients with coronary artery disease

Anti-platelet therapy is an important strategy for patients with coronary artery disease, who are at risk of coronary thrombosis. However, currently available therapies – such as clopidogrel – have a slow onset and are irreversible. 

Researchers report in Arteriosclerosis, Thrombosis and Vascular Biology (online, 17 December 2015[1]) on a first-in-man study of a new anti-platelet drug called PZ-128. It has a novel mode of action, targeting the protease-activated receptor-1. 

PZ-128 was administered to participants with coronary artery disease or associated risk factors via intravenous infusion for 1-2 hours. The infusion resulted in a dose-dependent and rapid inhibition of platelet aggregation. However, this was reversible, with platelet function recovered within 24 hours of the last 0.5mg/kg dose. 

The drug will now be tested in a phase II study of patients with acute coronary syndromes, including those undergoing percutaneous coronary intervention.

 

Citation: Clinical Pharmacist DOI: 10.1211/PJ.2015.20200338

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • New anti-platelet drug set for phase II study after success in patients with coronary heart disease. Pictured, a blood clot in coronary artery.

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.